

Anaerobic Organism – Data from U.S. Reference Laboratories

Cumulative data from Clinical and Laboratory Standards Institute (CLSI) from Jan 2017 – Dec 2024¹

Organism	% Susceptible							
	Penicillin	Amoxicillin/ Clavulanate	Piperacillin/ Tazobactam	Ceftriaxone	Meropenem	Ertapenem	Clindamycin	Metronidazole
BACTEROIDES SPECIES AND PARABACTEROIDES SPECIES								
<i>B. fragilis</i>	0	75	97	44	92	95	66	98
<i>B. ovatus</i>	--	64	94	--	99	--	32	100
<i>B. thetaiotaomicron</i>	0	67	75	1	96	94	16	100
<i>B. uniformis</i>	--	72	99	14	99	--	43	100
<i>Parabacteriodes distasonis</i>	0	49	72	32	98	--	25	100
<i>Phocaeicola dorei/vulgatus</i> (formerly <i>B. vulgatus</i>)	0	58	89	30	98	97	49	100
PREVOTELLA SPECIES								
<i>P. bivia</i>	11	--	100	--	100	100	45	97
<i>P. denticola</i>	26	--	100	--	100	--	51	100
<i>P. melaninogenica</i>	9	--	100	--	100	--	65	100
<i>P. nigrescens</i>	32	--	100	--	100	--	55	100
OTHER ANAEROBIC GRAM-NEGATIVE BACILLI								
<i>Alistipes</i> spp. ²	27	--	91	--	--	--	73	100
<i>Desulfovibrio desulfuricans</i>	10	--	41	--	--	--	94	100
<i>Dialister pneumosintes</i>	86	--	89	--	--	--	97	97
<i>Fusobacterium necrophorum</i>	93	100	98	99	100	--	99	100
<i>Fusobacterium nucleatum</i>	89	100	97	100	100	-- ³	98	100
VEILLONELLA SPECIES								
<i>Veillonella</i> spp. ⁴	28	96	76	98	99	95	91	96

-- Data not available

1. Data from three U.S. reference laboratories for Clinical and Laboratory Standards Institute, number of isolates differed for each bug-drug result.

2. Includes the following organisms: *Alistipes* spp., *A. finegoldii*, and *A. onderdonkii*

3. Nine-nine percent of *F. nucleatum* isolates tested susceptible to ertapenem. Isolates were from a single site (n = 500).

4. Includes the following organisms: *Veillonella* spp., *V. atypica*, *V. dispar*, and *V. parvula*

Organism	% Susceptible							
	Penicillin	Amoxicillin/ Clavulanate	Piperacillin/ Tazobactam	Ceftriaxone	Meropenem	Ertapenem	Clindamycin	Metronidazole
CLOSTRIDIUM SPECIES								
<i>Clostridioides difficile</i> (formerly <i>Clostridium difficile</i>) ⁵	8	--	98	--	98	--	21	99
<i>Clostridium innoculum</i>	64	--	100	90	96	--	72	99
<i>Clostridium perfringens</i>	96	100	100	99	100	100	82	100
<i>Clostridium ramosum</i>	93	100	100	100	99	--	14	99
<i>Clostridium septicum</i>	98	--	100	--	--	--	99	99
<i>Clostridium tertium</i>	22	100	99	57	99	--	8	99
ANAEROBIC GRAM-POSITIVE BACILLI OTHER THAN CLOSTRIDIUM SPECIES								
<i>Cutibacterium acnes</i> (formerly <i>Propionibacterium acnes</i>) ⁶	100	100	100	100	--	100	90	2
<i>Cutibacterium avidum</i>	100	100	100	100	--	100	60	0
<i>Eggerthella lenta</i>	2	100	65	15	--	100	90	99
<i>Slackia exigua</i>	99	100	100	100	--	--	99	100
ANAEROBIC GRAM-POSITIVE COCCI								
<i>Anaerococcus vaginalis</i>	99	100	100	100	100	--	82	99
<i>Finegoldia magna</i>	99	100	100	100	100	100	58	100
<i>Helcococcus</i> spp. ⁷	100	100	100	100	100	--	66	10
<i>Parvimonas micra</i>	99	100	100	100	100	100	90	100
<i>Peptoniphilus harei/indolicus</i>	98	--	100	100	100	--	70	100
<i>Peptostreptococcus anaerobius</i>	76	75	98	99	100	--	90	100

-- Data not available

5. Vancomycin MICs for 3033 *C. difficile* isolates demonstrated 98% wild-type (MIC ≤2 mcg/mL) and 2% non-wild-type (MIC ≥4 mcg/mL). The majority of isolates (76%) were from intestinal sources.

6. Vancomycin MICs for 1903 *C. acnes* isolates demonstrated 100% wild-type (MIC ≤ mcg/mL).

7. Includes the following organisms: *Helcococcus* spp., *Helcococcus kunzii*, and *Helcococcus sueciensis*.

Reference: CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 36th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2026.

Updated 1/30/2026